New gene-editing therapy wins endorsement from Catholic moralist
December 12, 2023
» Continue to this story on CNA
CWN Editor's Note: A promising new gene therapy, developed as a treatment for sickle-cell anemia, has been welcomed as a “very licit therapy” by the president of the National Catholic Bioethics Center.
The “Casgevy” therapy, the first such therapy to win federal approval in the US, uses genome-editing technology to modify the patient’s blood cells. It is available for use by patients 12 years old or older who face grave illness from the sickle-cell disease.
Dr. Joseph Meaney points out that while some gene-editing techniques are aimed to “human enhancement,” and have been condemned by the Church, this therapy is used simply to treat a disease.
The above note supplements, highlights, or corrects details in the original source (link above). About CWN news coverage.
For all current news, visit our News home page.
All comments are moderated. To lighten our editing burden, only current donors are allowed to Sound Off. If you are a current donor, log in to see the comment form; otherwise please support our work, and Sound Off!
